Clinical trials: Tumor Pancreas
Locally Advanced Malignant Solid Neoplasm, Metastatic Pancreatic Adenocarcinoma
CMP-001 and INCAGN01949 for Patients With Stage IV Pancreatic Cancer and Other Cancers Except Melanoma
This phase Ib/II trial studies the side effects and best dose of CMP-001 and how well it works when given together with INCAGN01949 in treating patients with stage IV pancreatic cancer and other cancers except melanoma.
- Conditions
- Locally Advanced Malignant Solid Neoplasm, Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8, Unresectable Malignant Solid Neoplasm
- Trial name
- NCT04387071
- Testing
- Agonistic Anti-OX40 Monoclonal Antibody INCAGN01949, VLP-encapsulated TLR9 Agonist CMP-001
- Where
- 4 sites in United States
- Volunteers
- 2 people
- Sponsor
- University of Southern California
Pain, Visceral Pain
TMS for the Treatment of Pancreatic Cancer Pain
This is a phase II study that aims to investigate prospectively a new therapy for a cohort of patients with chronic pain attributed to pancreatic cancer.
- Conditions
- Pain, Visceral Pain, Pancreatic Cancer
- Trial name
- NCT00324428
- Testing
- Transcranial Magnetic Stimulation
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Beth Israel Deaconess Medical Center
Pancreatic Acinar Carcinoma, Pancreatic Neoplasms
Acelarin First Line Randomised Pancreatic Study
The primary purpose of this study is to assess whether Acelarin (NUC-1031) is superior to gemcitabine in terms of overall survival for treatment of patients with metastatic pancreatic carcinoma.
- Trial name
- ACELARATE (NCT03610100)
- Testing
- Acelarin, Gemcitabine
- Where
- United Kingdom
- Volunteers
- 328 people
- Sponsor
- The Clatterbridge Cancer Centre NHS Foundation Trust
Pancreatic Adenocarcinoma
Radiopaque Hydrogel in Patients Undergoing Radiotherapy for Pancreatic Cancer
The goal of this pilot imaging study is to evaluate the visibility of marking the interface between the pancreas and duodenum with TraceIT Tissue Marker.
- Trial name
- NCT03307564
- Testing
- TraceIT tissue marker injection
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma
Dinaciclib and Akt Inhibitor MK2206 in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery
This randomized phase I trial studies the side effects and best dose of dinaciclib and Akt inhibitor MK2206 in treating patients with pancreatic cancer that cannot be removed by surgery.
- Conditions
- Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma, Stage III Pancreatic Cancer AJCC v6 and v7, Stage IV Pancreatic Cancer AJCC v6 and v7
- Trial name
- NCT01783171
- Testing
- Akt Inhibitor MK2206, Dinaciclib, Laboratory Biomarker Analysis
- Where
- 5 sites in United States, Canada
- Volunteers
- 42 people
- Sponsor
- National Cancer Institute (NCI)
Gastrointestinal Carcinoma, Pancreatic Cancer
A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies
Background: Gastrointestinal (GI) cancer affects the organs (such as the stomach, large and small intestine, pancreas, colon, liver, and biliary system) of the digestive tract.
- Conditions
- Gastrointestinal Carcinoma, Pancreatic Cancer, Hepatocellular Cancer, Cholangiocarcinoma
- Trial name
- NCT06690281
- Testing
- KRAS TCR-Transduced PBL, Aldesleukin, Fludarabine
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Solid Tumors
Study to Evaluate Relacorilant (CORT125134) in Combination With Nab-paclitaxel in Participants With Solid Tumors
The purpose of this study was to assess the safety of the combination of relacorilant (CORT125134), a novel glucocorticoid receptor (GR) antagonist, and nab- paclitaxel in participants with solid tumors and to determine the…
- Trial name
- NCT02762981
- Testing
- Relacorilant with nab-paclitaxel
- Where
- 4 sites in United States
- Volunteers
- 85 people
- Sponsor
- Corcept Therapeutics
Gastric Cancer, Colon Cancer
Resilience and Equity in Aging, Cancer, and Health (REACH)
The purpose of this multi-phase research study is to understand how consultation of cancer care with a geriatrician can best improve outcomes for older adults with gastrointestinal malignancies.
- Conditions
- Gastric Cancer, Colon Cancer, Esophageal Cancer, Rectal Cancer
- Trial name
- REACH (NCT04674267)
- Testing
- Phase 2 Intervention - Geriatric Co-Management
- Where
- United States
- Volunteers
- 147 people
- Sponsor
- Dana-Farber Cancer Institute
Cancer of Digestive System, Ovarian Cancer
Feasibility Study for Robotic Endomicroscopy to Better Define Resection Strategies (PERSEE)
This study aims at demonstrating the feasibility of probe-based confocal laser endomicroscopy (pCLE) and needle-based confocal laser endomicroscopy (nCLE).
- Trial name
- PERSEE (NCT02312167)
- Testing
- confocal laser endomicroscopy
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Institut Mutualiste Montsouris
Liver Metastases, Pancreatic Neoplasms
Role of EUS in Detection of Liver Metastasis
Liver metastasis may not be detected by CT and MRI due to their small size while they can be detected by EUS. Also, EUS-FNA has a great impact in improving the diagnostic accuracy of EUS.
- Trial name
- NCT04509492
- Testing
- Endoscopic ultrasound ( EUS )
- Where
- Egypt
- Volunteers
- 400 people
- Sponsor
- Mahmoud Wahba
Pancreatic Cancer
Intraoperative Celiac Plexus Neurolysis for Patients With Operable Pancreatic and Periampullary Cancer
Determine if the addition of an intraoperative ethanol celiac plexus neurolysis (alcohol block) in patients undergoing surgical intervention for pancreatic cancer will result in a decrease in cancer associated pain
- Trial name
- NCT00806611
- Testing
- Alcohol Block
- Where
- United States
- Volunteers
- 438 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Pancreatic Cancer
LDE225 With Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan for Untreated Advanced Pancreatic Cancer
LDE225 is a new medicine that blocks the Hedgehog (Hh) pathway. The Hh pathway is a cascade of molecular events that control cell growth and have been linked with the development of many human cancers, including pancreatic…
- Trial name
- NCT01485744
- Testing
- LDE225; Fluorouracil; Leucovorin; Oxaliplatin; Irinotecan
- Where
- 2 sites in United States
- Volunteers
- 39 people
- Sponsor
- Massachusetts General Hospital
Pancreatic Cancer
Study of HuMab-5B1 (MVT-5873) in Subjects With Pancreatic Cancer or Other Cancer Antigen 19-9 (CA19-9) Positive Malignancies
Phase 1 Safety and Tolerability Study in Subjects with Pancreatic Cancer or Other CA19-9 Positive Malignancies.
- Trial name
- NCT02672917
- Testing
- MVT-5873, modified FOLFIRINOX (mFOLFIRINOX), gemcitabine + nab-paclitaxel
- Where
- 5 sites in United States
- Volunteers
- 118 people
- Sponsor
- BioNTech Research & Development, Inc.
Pancreatic Ductal Adenocarcinoma
Oncolytic Virotherapy Plus PD-1 Inhibitor and Lenvatinib for Patients With Advanced Pancreatic Cancer
The objective of this study is to evaluate the safety/tolerability efficacy of oncolytic virotherapy combined with Tislelizumab plus lenvatinib for advanced pancreatic cancer patients who were relapsed or refractory to standard…
- Trial name
- NCT05303090
- Testing
- H101, Tislelizumab, lenvatinib
- Where
- China
- Volunteers
- 56 people
- Sponsor
- Fudan University
B Cell Lymphoma, B Cell Leukemia
Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors
A single arm, open-label pilot study is designed to determine the safety, efficacy and cytokinetics of CAR T cells in patients with malignant tumors with positive antigen targets.
- Conditions
- B Cell Lymphoma, B Cell Leukemia, Myeloma, Hepatocellular Carcinoma
- Trial name
- NCT03302403
- Testing
- CAR-CD19 T cell, CAR-BCMA T cell, CAR-GPC3 T cell
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Kang YU
Advanced Bile Duct Carcinoma, Stage II Esophageal Cancer AJCC v7
Ropidoxuridine in Treating Patients With Advanced Gastrointestinal Cancer Undergoing Radiation Therapy
This phase I trial studies the side effects and best dose of ropidoxuridine in treating patients with gastrointestinal cancer that has spread to other places in the body and usually cannot be cured or controlled with treatment…
- Conditions
- Advanced Bile Duct Carcinoma, Stage II Esophageal Cancer AJCC v7, Stage II Pancreatic Cancer AJCC v6 and v7, Stage IIA Esophageal Cancer AJCC v7
- Trial name
- NCT02381561
- Testing
- Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- National Cancer Institute (NCI)
Pancreatic Cancer
Efficacy and Safety of PARPi to Treat Pancreatic Cancer
This is an open label, single arm, phase II trial of Olaparib for (PDAC) pancreatic ductal adenocarcinoma patients with BRCAness (breast cancer gene). All study subjects will receive Olaparib in a dose of 300 mg p.o twice daily.
- Trial name
- 10 (NCT02511223)
- Testing
- OLAPARIB
- Where
- Israel
- Volunteers
- 24 people
- Sponsor
- Sheba Medical Center
Pancreatic Neoplasms, Cholangiocarcinoma
Study of Gemcitabine With TheraSphere® (Yttrium-90)in Patients With Hepatic Tumors of Pancreatobiliary Origin
Therasphere is a form of treatment that has been designed to selectively deliver radiation to the cancer within the patient's liver.
- Trial name
- NCT01434459
- Testing
- Gemcitabine with TheraSphere
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Emory University
Pancreas Cancer
Pilot Study of 89-Zr Panitumumab in Pancreas Cancer
The main purpose of the study is to assess the safety of 89Zr-panitumumab as a molecular imaging agent in patients with (metastatic) pancreas cancer.
- Trial name
- NCT04833959
- Testing
- 89Zr-panitumumab
- Where
- United States
- Sponsor
- Stanford University
Pancreatic Cancer
Vitamin E δ-Tocotrienol Multiple Dose in Healthy Subjects
The Principal Investigator believes that Vitamin E δ-Tocotrienol will slow the progression of pancreatic cancer cells. Therefore, the investigators must determine the safety and tolerability of Vitamin E δ-Tocotrienol in healthy…
- Trial name
- NCT01450046
- Testing
- Vitamin E δ-Tocotrienol
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.